Legal & General Group Plc Has $4.89 Million Holdings in Arcus Biosciences, Inc. $RCUS

Legal & General Group Plc lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 15.0% during the 4th quarter, Holdings Channel reports. The fund owned 205,203 shares of the company’s stock after acquiring an additional 26,806 shares during the quarter. Legal & General Group Plc’s holdings in Arcus Biosciences were worth $4,890,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in RCUS. AQR Capital Management LLC grew its holdings in Arcus Biosciences by 253.9% during the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after acquiring an additional 65,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arcus Biosciences by 10.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after acquiring an additional 3,565 shares during the last quarter. Millennium Management LLC grew its holdings in Arcus Biosciences by 29.2% during the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after acquiring an additional 270,253 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Arcus Biosciences by 106.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after acquiring an additional 470,755 shares during the last quarter. Finally, Strs Ohio bought a new stake in Arcus Biosciences during the 1st quarter worth about $67,000. Institutional investors own 92.89% of the company’s stock.

Insider Activity

In related news, CFO Robert C. Goeltz II sold 7,763 shares of Arcus Biosciences stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the transaction, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. This trade represents a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of Arcus Biosciences stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,020,002.37. The trade was a 6.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Wedbush increased their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Leerink Partners set a $47.00 price objective on shares of Arcus Biosciences in a report on Monday, April 20th. Wells Fargo & Company set a $23.00 price objective on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a report on Monday, March 2nd. Finally, The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average price target of $35.10.

Arcus Biosciences Stock Down 0.2%

Shares of NYSE RCUS opened at $23.16 on Monday. The firm has a market capitalization of $2.91 billion, a PE ratio of -7.28 and a beta of 0.85. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a 1 year low of $7.91 and a 1 year high of $28.72. The firm’s 50-day moving average is $23.84 and its 200-day moving average is $22.85.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million during the quarter, compared to the consensus estimate of $29.49 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm’s revenue for the quarter was down 39.3% compared to the same quarter last year. During the same period last year, the business posted ($1.14) EPS. Equities analysts expect that Arcus Biosciences, Inc. will post -3.61 EPS for the current year.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: LifescI Capital maintained an Outperform rating on Arcus Biosciences and set a $46 price target, signaling meaningful upside from current levels.
• Neutral Sentiment: The analyst’s updated forecasts for 2026-2030 remain broadly consistent across periods, suggesting no major near-term change in the long-term view on the company’s earnings trajectory.
• Negative Sentiment: Despite the upbeat rating, Lifesci Capital expects negative EPS in every period it covered, including losses of about ($4.15) in FY2026 and ($4.55) in FY2027, reinforcing concerns about profitability.
• Negative Sentiment: The estimates sit below zero even in later years, with projected losses of roughly ($4.52) in FY2028, ($4.56) in FY2029, and ($4.45) in FY2030, which may be keeping pressure on the stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.